Comparative Biochemical and Behavioral Studies of Chronic Schizophrenic Patients and Normals
The pathfinding experiments of Kety and his co-workers (Pollin, Cardon and Kety, 1961) revealed that the administration of amino acids, including methionine or tryptophan, with a monoamine oxidase inhibitor, iproniazid (Marsilid), caused behavioral worsening, representing either a “biochemically-induced acute flare-up of a chronic schizophrenic process on the one hand, or a toxic delirium superimposed upon chronic schizophrenia on the other.” We used their method but gave the patients L-cysteine as the amino acid and tranylcypromine (Parnate) as the monoamine oxidase inhibitor. We added an additional facet by determining the changes in the urinary contents of these patients that took place simultaneously with the worsening of the symptoms. In all observations, psycho-pharmacological agents were replaced by similar looking placebos. All diagnoses were made according to the Diagnostic and Statistical Manual of Mental Disorders prepared by a committee of the American Psychiatric Association.
KeywordsUrine Sample Schizophrenic Patient Tertiary Amine Monoamine Oxidase Inhibitor Chronic Schizophrenic Patient
Unable to display preview. Download preview PDF.
- “Diagnostic and Statistical Manual of Mental Disorders,” Second Edition, 1968, The Committee on Nomenclature and Statistics of the American Psychiatric Association, American Psychiatric Association, Washington, D. C.Google Scholar
- Mandell, A. J., and Morgan, M., 1971, Indole(ethyl)amine N-methyl-transferase in human brain, Nature, (New Biology), 230: 85.Google Scholar
- Narasimhachari, N., and Himwich, H. E., 1973, GC-MS identification of bufotenin in urine samples from patients with schizophrenia or infantile autism, Life Sei. 12 (Part II): 475.Google Scholar
- Narasimhachari, N., and Himwich, H. E., GC-MS identification of DMT in urine samples from drug-free chronic schizophrenic patients and its quantitation by the technique of single (selective) ion monitoring, Biochem. Biophys. Res. Commun, in press.Google Scholar
- Narasimhachari, N., Spaide, J., and Heller, B., 1971c, Gas liquid chromatographic and mass spectrometric studies on trimethylsilyl derivatives of N-methyl- and N,N-dimethyltryptamines, J. Chromatog. Sci. 9: 502.Google Scholar
- Narasimhachari, N. Avalos, J., Fujimori, M., and Himwich, H. E., 1972, Studies of drug-free schizophrenics and controls, Biol. Psychiat. 5: 311.Google Scholar
- Narasimhachari, N., Baumann, P., Pak, H. S., Carpenter, W. T., Zocchi, A. F., Hokanson, L., Fujimori, M., and Himwich, H. E., Gas chromatographic-mass spectrometric identification of urinary bufotenin and dimethyltryptamine in drug-free chronic schizophrenic patients, Biol. Psychiat. in press.Google Scholar
- Shulgin, A., 1970, Discussion, in “Psychotomimetic Drugs”, D. H. Efron ed., p. 119, Raven Press, New York.Google Scholar
- Szara, S., 1961, Hallucinogenic effects and metabolism of tryptamine derivatives in man, Fed. Proc. 20: 885.Google Scholar
- Szara, S., 1967, Hallucinogenic amines and schizophrenia (with a brief addendum on N-dimethyltryptamine), in “Amines and Schizophrenia,” H. E. Himwich, S. S. Kety, and J. R. Smythies eds., pp. 181–197, Pergamon Press, New York.Google Scholar